MX2017006015A - Composiciones para usar en el tratamiento de cancer renal. - Google Patents

Composiciones para usar en el tratamiento de cancer renal.

Info

Publication number
MX2017006015A
MX2017006015A MX2017006015A MX2017006015A MX2017006015A MX 2017006015 A MX2017006015 A MX 2017006015A MX 2017006015 A MX2017006015 A MX 2017006015A MX 2017006015 A MX2017006015 A MX 2017006015A MX 2017006015 A MX2017006015 A MX 2017006015A
Authority
MX
Mexico
Prior art keywords
apilimod
renal cancer
treatment
methods
present disclosure
Prior art date
Application number
MX2017006015A
Other languages
English (en)
Inventor
Beckett Paul
Lichenstein Henri
Xu Tian
Gayle Sophia
BEEHARRY Neil
LANDRETTE Sean
Conrad Chris
M Rothberg Jonathan
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of MX2017006015A publication Critical patent/MX2017006015A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción se refiere a métodos para tratar cáncer renal con apilimod y composiciones y métodos relacionados.
MX2017006015A 2014-11-07 2015-11-06 Composiciones para usar en el tratamiento de cancer renal. MX2017006015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
PCT/US2015/059512 WO2016073877A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of renal cancer

Publications (1)

Publication Number Publication Date
MX2017006015A true MX2017006015A (es) 2017-11-17

Family

ID=54548302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006015A MX2017006015A (es) 2014-11-07 2015-11-06 Composiciones para usar en el tratamiento de cancer renal.

Country Status (16)

Country Link
US (3) US10206910B2 (es)
EP (2) EP3215158B1 (es)
JP (1) JP6705828B2 (es)
KR (1) KR20170098812A (es)
CN (1) CN107249638B (es)
AU (1) AU2015342869A1 (es)
BR (1) BR112017008799A2 (es)
CA (1) CA2966359A1 (es)
ES (1) ES2741399T3 (es)
HU (1) HUE044557T2 (es)
IL (1) IL251905B (es)
MX (1) MX2017006015A (es)
PL (1) PL3215158T3 (es)
PT (1) PT3215158T (es)
RU (1) RU2727802C2 (es)
WO (1) WO2016073877A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016017112A2 (pt) 2014-01-24 2017-08-08 Ai Therapeutics Inc Composições de apilimod e métodos de uso das mesmas
ES2734081T3 (es) * 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
EP3215158B1 (en) 2014-11-07 2019-05-08 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
TW201726142A (zh) * 2016-01-21 2017-08-01 藍治療公司 用於以阿吡莫德治療癌症的生物標記
CA3034453A1 (en) * 2016-08-25 2018-03-01 AI Therapeutics, Inc. Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling
MX2019004179A (es) * 2016-10-12 2019-09-02 Ai Therapeutics Inc Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
JP7108680B2 (ja) 2017-03-24 2022-07-28 ピクサイ インコーポレイテッド 有用な医薬用途を有する縮合トリアゾロ－ピリミジン化合物
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
CN111801098A (zh) 2018-02-21 2020-10-20 人工智能治疗公司 使用阿匹莫德和谷氨酸能剂的组合疗法
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
CN114306370A (zh) * 2021-12-31 2022-04-12 北京悦康科创医药科技股份有限公司 反义寡核苷酸在制备治疗肾癌药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DK1921169T3 (da) 1993-11-12 2012-06-04 Phri Properties Inc Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
JP4996261B2 (ja) 2004-02-06 2012-08-08 エラン ファーマシューティカルズ，インコーポレイテッド 腫瘍および転移性疾患を処置するための方法および組成物
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc DERIVATIVES OF QUINAZOLIN AS METABOLICALLY INERT ANTIFOLIC
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AU2006316605B2 (en) 2005-11-17 2012-04-26 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP1981890A2 (en) 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
WO2008008433A2 (en) 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
ATE551334T1 (de) 2007-02-06 2012-04-15 Novartis Ag Pi3-kinase-hemmer und verfahren zu ihrer verwendung
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5258331B2 (ja) 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EA025443B1 (ru) 2010-03-08 2016-12-30 Слоан-Кеттеринг Институт Фор Кэнсер ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА КИНАЗЫ Cdc7 ГРАНАТИЦИНА B
WO2011122620A1 (ja) * 2010-03-29 2011-10-06 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
US8709419B2 (en) * 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
CA2817931C (en) 2010-11-19 2017-10-31 Ecole Polytechnique Federale De Lausanne (Epfl) 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201700698WA (en) 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014055913A1 (en) 2012-10-05 2014-04-10 Cerulean Pharma Inc. Treatment of cancer
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
BR112016017112A2 (pt) * 2014-01-24 2017-08-08 Ai Therapeutics Inc Composições de apilimod e métodos de uso das mesmas
ES2734081T3 (es) 2014-11-07 2019-12-04 Ai Therapeutics Inc Apilimod para el uso en el tratamiento de melanoma
EP3215158B1 (en) 2014-11-07 2019-05-08 AI Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
KR101761573B1 (ko) 2014-12-29 2017-07-26 주식회사 인트론바이오테크놀로지 신규한 장출혈성 대장균 박테리오파지 Ｅｓｃ-ＣＨＰ-1 및 이의 장출혈성 대장균 증식 억제 용도
WO2016126707A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
EP3817736A4 (en) 2018-07-05 2021-07-28 Mayo Foundation for Medical Education and Research PIKFYVE INHIBITORS
US20210077500A1 (en) 2019-09-12 2021-03-18 Al Therapeutics, Inc. Pikfyve inhibitors for cancer therapy

Also Published As

Publication number Publication date
BR112017008799A2 (pt) 2017-12-19
US20190201385A1 (en) 2019-07-04
CN107249638A (zh) 2017-10-13
IL251905A0 (en) 2017-06-29
HUE044557T2 (hu) 2019-11-28
IL251905B (en) 2021-03-25
US20170333408A1 (en) 2017-11-23
PT3215158T (pt) 2019-08-23
US20200297706A1 (en) 2020-09-24
EP3581184B1 (en) 2021-02-24
CA2966359A1 (en) 2016-05-12
EP3215158A1 (en) 2017-09-13
PL3215158T3 (pl) 2019-11-29
RU2017119065A3 (es) 2019-06-05
US11166944B2 (en) 2021-11-09
CN107249638B (zh) 2021-05-14
US10206910B2 (en) 2019-02-19
AU2015342869A1 (en) 2017-06-15
JP6705828B2 (ja) 2020-06-03
EP3581184A1 (en) 2019-12-18
JP2017535601A (ja) 2017-11-30
KR20170098812A (ko) 2017-08-30
RU2017119065A (ru) 2018-12-07
EP3215158B1 (en) 2019-05-08
ES2741399T3 (es) 2020-02-10
WO2016073877A1 (en) 2016-05-12
RU2727802C2 (ru) 2020-07-24

Similar Documents

Publication Publication Date Title
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
NZ731467A (en) Anti-tim3 antibodies and methods of use
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PT3200815T (pt) Métodos e composições para o tratamento de cancro
IL276733A (en) Use of Aribolin in cancer treatment
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
MX2017000306A (es) Metodos para tratar hipotension.
PH12016501838A1 (en) Compounds and their methods of use
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
EA201691907A1 (ru) Комбинированная терапия кураксинами
ZA201403006B (en) Composition for use in treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: COVESTRO (NETHERLANDS) B.V.

FG Grant or registration